Corporate News Blog Moleculin Biotech Signs Agreement with the - Erie News Now | WICU & WSEE in Erie, PA

Corporate News Blog Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin

Posted: Updated:

LONDON, UK / ACCESSWIRE / October 5, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Moleculin Biotech, Inc. (NASDAQ: MBRX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MBRX. The Company announced on October 03, 2017, that it has entered into an agreement with a Poland-based hospital to conduct clinical trials for evaluating the efficacy of its lead product candidate Annamycin in treating acute myeloid leukemia (AML). This is the first of several hospitals desiring to be treatment centers for the trial. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBRX. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=MBRX

FDA Approval for Clinical Trials for Annamycin

Moleculin declared that the Food and Drug Administration (FDA) has allowed it to begin clinical trials of Annamycin for the treatment of relapsed or refractory Acute Myeloid Leukemia on September 26, 2017. The FDA approval came after the agency concluded its safety review of information and a proposed protocol submitted by Moleculin in an Investigational New Drug (IND) application.

Walter Klemp, Chairman and CEO of Moleculin shared his views about the approval. He disclosed that this is a significant milestone for Moleculin, whose main focus has been to get Annamycin back into the clinic so that it can commence optimizing the dosing of the drug. This is the follow-up step for assessing Annamycin’s potential for becoming the first 2nd line therapy suitable for relapsed or refractory AML patients. He was thrilled that one could now refer to Moleculin as a ‘clinical-stage’ Company.

Moleculin’s Lookout for Treatment Sites

Walter Klemp stated that since FDA has approved their investigational new drug application, Moleculin is now commencing the process of opening treatment centers and recruiting patients. He revealed that the Company has identified around 14 sites that meet the criteria. In fact, some of these sites have already expressed an interest in participating. Thus, the Company would enter into agreements with a lot more treatment centers in the near future.

First Facility for Clinical Trial in Poland

The first facility selected for the Clinical trial of Annamycin is a hematology clinic in a major hospital in Poznan, Poland. Moleculin entered into this first agreement with the Hospital of the Transfiguration of the Lord – Medical University in Poznan, Department of Hematology and Marrow Transplantation. However, to treat patients in this hospital or any other site in Poland, Moleculin would need a separate regulatory approval in Poland based on the approved US IND.

Walter Klemp highlighted that the process is Poland is somewhat different from that in the US. That is how Moleculin was able to get the Poland site signed up soon after receiving the approval from FDA. The Company intends to make similar announcements for additional sites in the coming months. In fact, it plans to get a total of seven treatment sites in Poland itself.

About Moleculin Biotech, Inc.

Moleculin Biotech is a clinical-stage pharmaceutical Company that works towards the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Its lead product Annamycin is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia. The Company also has two preclinical small molecule portfolios in development, one of which is concentrated on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. The other portfolio targets the metabolism of tumors.

Last Close Stock Review

At the closing bell, on Wednesday, October 04, 2017, Moleculin Biotech’s stock dropped 2.41%, ending the trading session at $2.43. A total volume of 364.28 thousand shares have exchanged hands. The Company’s stock price skyrocketed 48.17% in the last three months and 147.96% in the past six months. Moreover, the stock gained 6.58% since the start of the year. The stock currently has a market cap of $51.35 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 477147

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com